We demonstrated that ITM2A expression significantly correlates with PR status, but not with ER status and HER2 level, suggesting that it could be more effective to use hormone therapy for breast cancer patients with PR positive status and low ITM2A expression. Here, ESR1 is linked to breast cancer.